Review Article

Tirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside

Figure 4

Updated OS in 19 patients receiving Imatinib for steroid-refractory cGVHD (Olivieri et al. [109]).
924954.fig.004